

EAST

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1722	((544/323) or (514/275)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2005/09/25 11:50



National  
Library  
of Medicine



My N  
[Sign In] [Regi]

All Databases

PubMed

Nucleotide

Protein

Genome

Structure

OMIM

PMC

Journals

Box

Search PubMed for #1 and #2 Preview Go Cl

Limits

Preview/Index

History

Clipboard

Details

About Entrez

Text Version

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

Search

Most Recent Queries

Time Result

#3 Search #1 and #2

11:54:53 11

#2 Search stimulating neuronal function

11:54:40 1359

#1 Search pyrimidine

11:53:45 137453

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

Special Queries

LinkOut

My NCBI (Cubby)

Clear History

Related Resources

Order Documents

NLM Mobile

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central



Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Sep 14 2005 04:34:46

[All Databases](#)[PubMed](#)[Nucleotide](#)[Protein](#)[Genome](#)[Structure](#)[OMIM](#)[PMC](#)[Journals](#)[B](#)

Search  for

[Limits](#)[Preview/Index](#)[History](#)[Clipboard](#)[Details](#)

Display

Sort by

[About Entrez](#)[Text Version](#)[Entrez PubMed](#)[Overview](#)[Help | FAQ](#)[Tutorial](#)[New/Noteworthy](#)[E-Utilities](#)[PubMed Services](#)[Journals Database](#)[MeSH Database](#)[Single Citation Matcher](#)[Batch Citation Matcher](#)[Clinical Queries](#)[Special Queries](#)[LinkOut](#)[My NCBI \(Cubby\)](#)[Related Resources](#)[Order Documents](#)[NLM Mobile](#)[NLM Catalog](#)[NLM Gateway](#)[TOXNET](#)[Consumer Health](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[PubMed Central](#)

Items 1 - 11 of 11

One page.

☐ 1: [Petroff BK, Crutch CR, Hunter DM, Wierman ME, Gao X.](#)[Related Articles, Links](#)

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) stimulates gonadotropin secretion in the immature female Sprague-Dawley rat through a pentobarbital- and estradiol-sensitive mechanism but does not alter gonadotropin-releasing hormone (GnRH) secretion by immortalized GnRH neurons in vitro.

Biol Reprod. 2003 Jun;68(6):2100-6. Epub 2003 Jan 22.

PMID: 12606454 [PubMed - indexed for MEDLINE]

☐ 2: [Klementiev B, Bichevaja N, Novikova T, Chebotar N, Bock E, Berezin V.](#)[Related Articles, Links](#)

A peptide agonist of the neural cell adhesion molecule (NCAM), C3, protects against developmental defects induced by a teratogen pyrimethamine.

Int J Dev Neurosci. 2002 Nov;20(7):527-36.

PMID: 12485621 [PubMed - indexed for MEDLINE]

☐ 3: [Mignon L, Wolf WA.](#)[Related Articles, Links](#)

Postsynaptic 5-HT(1A) receptors mediate an increase in locomotor activity in the monoamine-depleted rat.

Psychopharmacology (Berl). 2002 Aug;163(1):85-94. Epub 2002 Jul 13.

PMID: 12185404 [PubMed - indexed for MEDLINE]

☐ 4: [Spencer JP, Whiteman M, Jenner P, Halliwell B.](#)[Related Articles, Links](#)

5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons.

J Neurochem. 2002 Apr;81(1):122-9.

PMID: 12067224 [PubMed - indexed for MEDLINE]

☐ 5: [Fiorica-Howells E, Maroteaux L, Gershon MD.](#)[Related Articles, Links](#)

Serotonin and the 5-HT(2B) receptor in the development of enteric neurons.

J Neurosci. 2000 Jan 1;20(1):294-305.

PMID: 10627607 [PubMed - indexed for MEDLINE]

☐ 6: [Markianos M, Hatzimanolis J, Lykouras L.](#)[Related Articles, Links](#)

Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone.

Psychopharmacology (Berl). 1999 Apr;143(3):270-2.

PMID: 10353429 [PubMed - indexed for MEDLINE]

☐ 7: [Lochhead KM, Zager RA.](#)

[Related Articles](#), [Links](#)



Fluorinated anesthetic exposure "activates" the renal cortical sphingomyelinase cascade.

Kidney Int. 1998 Aug;54(2):373-81.

PMID: 9690203 [PubMed - indexed for MEDLINE]

☐ 8: [Xu F, Frazier DT.](#)

[Related Articles](#), [Links](#)



Medullary respiratory neuronal activity modulated by stimulation of the fastigial nucleus of the cerebellum.

Brain Res. 1995 Dec 24;705(1-2):53-64.

PMID: 8821733 [PubMed - indexed for MEDLINE]

☐ 9: [De Gennaro Colonna V, Bertola G, Coco CB, Bifano M, Cocchi D, Maggi A, Muller EE.](#)

[Related Articles](#), [Links](#)



Changes in the hypothalamic-pituitary somatotrophic function of infant hypothyroid rats.

Proc Soc Exp Biol Med. 1990 Mar;193(3):214-9.

PMID: 1968255 [PubMed - indexed for MEDLINE]

☐ 10: [Gottesfeld Z, Butler IJ, Findley WE.](#)

[Related Articles](#), [Links](#)



Prenatal and postnatal hypothyroidism abolishes lesion-induced noradrenergic sprouting in the adult rat.

J Neurosci Res. 1985;14(1):61-9.

PMID: 4020898 [PubMed - indexed for MEDLINE]

☐ 11: [Gotz D, Ziesch C, Wenzel M, Grosse G, Schuster T, Wenzel J.](#)

[Related Articles](#), [Links](#)



[Electron microscopic and morphometric studies on the in vitro differentiation of mitochondria in neurons of hippocampus explant cultures as affected by orotic acid and sodium orotate]

Z Mikrosk Anat Forsch. 1982;96(4):613-32. German.

PMID: 6184903 [PubMed - indexed for MEDLINE]

Display ☐ Summary ☐ Show 20 ☐ Sort by ☐ Send to ☐

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)



[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Sep 14 2005 04:34:46

10648046

2:\STNEXP4\QUERIES\09907273 (subgenus).str



chain nodes :

7 8 9 10 12 16

ring nodes :

1 2 3 4 5 6

chain bonds :

2-16 6-7 7-8 8-9 9-10 9-12

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

2-16 6-7 7-8 9-10 9-12

exact bonds :

8-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:O,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS  
 12:CLASS 16:CLASS

10/643,046  
~~09907,273~~ (subgenus around elected species)

=>


Uploading 09907273.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 18:19:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5610 TO ITERATE

17.8% PROCESSED 1000 ITERATIONS

21 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 107712 TO 116688

PROJECTED ANSWERS: 1705 TO 3007

L2 21 SEA SSS SAM L1

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045

L3 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09907273.str

L4 STRUCTURE UPLOADED

=> que L4 NOT L3

L5 QUE L4 NOT L3

=> d l5


10/648,046

~~09907273~~ (subgenus around elected species).

L5 HAS NO ANSWERS

L3 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045

L4 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

L5 QUE L4 NOT L3

=> s 15 sss sam

SAMPLE SEARCH INITIATED 18:25:12 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 446 TO ITERATE

100.0% PROCESSED 446 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 7653 TO 10187

PROJECTED ANSWERS: 964 TO 1996

L6 50 SEA SSS SAM L4 NOT L3

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045

L7 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09907273 (subgenus).str

L8 STRUCTURE UPLOADED

=> que L8 NOT L7

L9 QUE L8 NOT L7


10/648,046  
~~09/007,273~~ (subgenus around elected species)

=> d 19

L9 HAS NO ANSWERS

L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045

L8 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

L9 QUE L8 NOT L7

=> s 19 sss sam

SAMPLE SEARCH INITIATED 18:27:10 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 368 TO ITERATE

100.0% PROCESSED 368 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 6210 TO 8510

PROJECTED ANSWERS: 964 TO 1996

L10 50 SEA SSS SAM L8 NOT L7

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045

L11 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09907273 (subgenus).str

L12 STRUCTURE UPLOADED

=> que L12 NOT L11

L13 QUE L12 NOT L11




10/648,046  
~~09/967,273~~ (subgenus around elected species)

=> d 113

L13 HAS NO ANSWERS

L11 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045

L12 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

L13 QUE L12 NOT L11

=> s 113 sss sam

SAMPLE SEARCH INITIATED 18:28:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 47 TO ITERATE

100.0% PROCESSED 47 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 529 TO 1351

PROJECTED ANSWERS: 3 TO 163

L14 3 SEA SSS SAM L12 NOT L11

=> s 113 sss ful

FULL SEARCH INITIATED 18:30:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1276 TO ITERATE

100.0% PROCESSED 1276 ITERATIONS

88 ANSWERS

SEARCH TIME: 00.00.01

L15 88 SEA SSS FUL L12 NOT L11

=> s 115

L16 40 L15

=> d 116 1-40 bib,ab,hitstr

L16 ANSWER 1 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 2003:76625 CAPLUS  
 DN 138:122653  
 TI Pyrimidine derivatives for treatment of neurodegenerative diseases  
 IN Fick, David B.; Foreman, Mark M.; Glasky, Alvin J.  
 PA Neotherapeutics, Inc., USA  
 SO PCT Int. Appl., 44 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

*Applicant's*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003007963	A1	20030130	WO 2002-US23246	20020717
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-907273 A 20010717 ← *Applicant's*

AB A pyrimidine deriv. or analog comprises an amino-substituted six-membered heterocyclic moiety, moiety A, linked through a linker -L-C(O)- to a moiety B, where C(O)-B is a carboxylic acid, a carboxylic acid ester, or a moiety of the structure N(Y1)-D, where Y1 can be one of a variety of substituents, including H or alkyl, and D is a moiety that enhances the pharmacol. effects, promotes absorption, or promotes blood-brain barrier penetration of the deriv. or analog. The moiety A can have two or three N atoms in the ring; typically, the moiety A is a pyrimidine moiety, with two N atoms in the ring. The moiety B can be one of a variety of moieties, including moieties having nootropic activity or other biol. or physiol. activity. All cited compds. (e.g. 4-[[3-[(2-amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid Et ester) have nootropic or anti-amnesic activity at doses of 10 mg/kg i.p. or less. Although the methods of prepn. are not claimed, 3 example prepn. are included.


IT **389799-47-7P**, 4-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic Acid Ethyl Ester **389799-50-2P**, 4-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid **389799-54-6P**, 3-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid ethyl ester **389799-57-9P**, 3-[[3-[(2-Amino-6-chloropyrimidin-4-yl)amino]propionyl]amino]benzoic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; pyrimidine derivs. for treatment of neurodegenerative diseases)

RN 389799-47-7 CAPLUS  
 CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


10/648,046

~~69,987,272~~ (subgenus around elected species)




RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 389799-54-6 CAPLUS


CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



*Elected species*

RN 389799-57-9 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/648,046

~~09/007,273~~ (subgenus around elected species)

L16 ANSWER 2 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 2002:215776 CAPLUS

DN 137:70674

TI Amino-substituted O6-benzyl-5-nitrosopyrimidines: interplay of molecular, molecular-electronic and supramolecular structures

AU Quesada, Antonio; Marchal, Antonio; Melguizo, Manuel; Nogueras, Manuel; Sanchez, Adolfo; Low, John N.; Cannon, Debbie; Farrell, Dorcas M. M.; Glidewell, Christopher

CS Departamento de Quimica Inorganica y Organica, Universidad de Jaen, Jaen, 23071, Spain

SO Acta Crystallographica, Section B: Structural Science (2002), B58(2), 300-315

CODEN: ASBSDK; ISSN: 0108-7681

PB Blackwell Munksgaard

DT Journal

LA English

AB The structures of eight 2,4,6-trisubstituted-5-nitrosopyrimidines (one of which crystallizes in two polymorphs) were detd., including seven O6-benzyl derivs. which are potential, or proven, in vitro inhibitors of the human DNA-repair protein O6-alkylguanine-DNA-transferase. In the derivs. having an amino substituent at the 4-position, an intramol. N-H...O H bond with the nitroso O as an acceptor leads to an overall mol. shape similar to that of substituted purines. There is a marked propensity for these nitroso compds. to crystallize with  $Z' = 2$ . The structure of an analog with no nitroso group is also reported for comparative purposes. Compds. contg. the N-alkyl substituents -NHCH<sub>2</sub>COOEt, -NHCH<sub>2</sub>CH<sub>2</sub>COOEt and -NHCH(CH<sub>2</sub>Ph)COOEt, derived from amino acid esters, exhibit a rich variety of conformational behavior, and in all of the nitroso compds. the bond lengths provide strong evidence for a highly polarized electronic structure. Assocd. with this polarization is extensive charge-assisted H bonding between the mols., leading to supramol. aggregation as finite (zero-dimensional) aggregates, chains, mol. ladders, sheets and frameworks.


IT 439666-61-2 439666-62-3 439666-63-4

RL: PRP (Properties)

(crystal structure of)

RN 439666-61-2 CAPLUS

CN Glycine, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 439666-62-3 CAPLUS

CN .beta.-Alanine, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

10/648,046


~~00/907,273~~ (subgenus around elected species)



RN 439666-63-4 CAPLUS

CN L-Phenylalanine, N-[2-amino-5-nitroso-6-(phenylmethoxy)-4-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:51464 CAPLUS  
 DN 136:112673  
 TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for treatment of disease-induced peripheral neuropathy and related conditions  
 IN Diamond, Jack; Glasky, Alvin J.  
 PA Neotherapeutics, Inc., USA  
 SO PCT Int. Appl., 69 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004452	A2	20020117	WO 2001-US21526	20010706
	WO 2002004452	A3	20030103		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002055506	A1	20020509	US 2001-900844	20010706 — AU 1617
	US 2002061899	A1	20020523	US 2001-899901	20010706 — AU 1614
PRAI	US 2000-216844P	P	20000707		

OS MARPAT 136:112673


AB A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The disease-induced peripheral neuropathy can be diabetic neuropathy or disease-induced peripheral neuropathy with another basis.

IT 389799-47-7 389799-50-2 389799-54-6  
 389799-57-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (purine derivs., pyrimidine derivs., and tetrahydroindolone derivs. for treatment of disease-induced peripheral neuropathy and related conditions)


RN 389799-47-7 CAPLUS

CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 4 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 2002:51463 CAPLUS

DN 136:112672

TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for stimulation of synthesis of synaptophysin in the central nervous system

IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 59 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


PATENT NO.                      KIND      DATE                      APPLICATION NO.      DATE  
 -----  
 PI      WO 2002004451              A2      20020117                      WO 2001-US21385      20010706  
          WO 2002004451              A3      20030103  
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
          CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
          HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
          LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
          SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
          YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
          DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
          BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
          US 2002040032              A1      20020404                      US 2001-899478      20010705 ← E. Abn.  
 PRAI US 2000-216808P      P      20000707                      (1614)  
 OS      MARPAT 136:112672  
 AB      A method of increasing the synthesis and/or secretion of synaptophysin  
          comprises administering to a patient with a neurol. disease or a patient  
          at risk of developing a neurol. disease an effective quantity of a purine  
          deriv. of analog, a tetrahydroindolone deriv. or analog, or a pyrimidine  
          deriv. or analog. If the compd. is a purine deriv., the purine moiety can  
          be guanine or hypoxanthine. The neurol. disease can be a  
          neurodegenerative disease such as Alzheimer's disease or a  
          neurodevelopmental disorder such as Down's syndrome. Typically, the  
          compd. can pass through the blood-brain barrier. A particularly preferred  
          purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.  
 IT      389799-47-7 389799-50-2 389799-54-6  
          389799-57-9  
          RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
          (Biological study); USES (Uses)  
          (purine deriv., pyrimidine deriv., or tetrahydroindolone deriv. for  
          stimulation of synthesis of synaptophysin in CNS)  
 RN      389799-47-7 CAPLUS  
 CN      Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-  
          oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)






RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




10/648,046

~~09/907,273~~ (subgenus around elected species)

L16 ANSWER 5 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 2002:51462 CAPLUS  
 DN 136:112671  
 TI Methods using a purine derivative, pyrimidine derivative, or tetrahydroindolone derivative for prevention of accumulation of amyloid .beta. peptide in the central nervous system  
 IN Glasky, Michelle; Lahiri, Debomoy K.; Farlow, Martin R.  
 PA Neotherapeutics, Inc., USA  
 SO PCT Int. Appl., 56 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO. : DATE
PI	WO 2002004450	A2	20020117	WO 2001-US21384 20010706
	WO 2002004450	A3	20021212	
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002040031	A1	20020404	US 2001-899611 20010705 — 1614.
PRAI	US 2000-216845P	P	20000707	
OS	MARPAT 136:112671			
AB	A method of either inhibiting the formation of A.beta. or stimulating the formation of sAPP comprises administering to a patient with a neurol. disease or a patient at risk of developing a neurol. disease an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The neurol. disease can be a neurodegenerative disease such as Alzheimer's disease or a neurodevelopmental disorder such as Down's syndrome. Typically, the compd. can pass through the blood-brain barrier. A particularly preferred purine deriv. is N-4- carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide.			
IT	389799-47-7 389799-50-2 389799-54-6 389799-57-9			
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (purine deriv., pyrimidine deriv., or tetrahydroindolone deriv. for prevention of accumulation of amyloid .beta. peptide in CNS)			
RN	389799-47-7 CAPLUS			
CN	Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)			



09/907,273 (subgenus around elected species)


RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 6 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 2002:51461 CAPLUS

DN 136:112691

TI Methods using a purine derivative, a pyrimidine derivative or a tetrahydroindolone derivative for treatment of conditions affected by activity of multidrug transporters

IN Taylor, Eve M.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004449	A2	20020117	WO 2001-US21383	20010706
	WO 2002004449	A3	20020613		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002128264 A1 20020912

US 2001-900297 20010706

PRAI US 2000-216616P P 20000707

OS MARPAT 136:112691

AB One aspect of the invention is a method of treating a condition or disease assocd. with the activity of a multidrug transporter protein comprising administering to a mammal with a condition or disease assocd. with the activity of a multidrug transporter protein an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. A particularly preferred bifunctional purine deriv. is N-4-carboxyphenyl-3-(6-oxohydropurin-9-yl)propanamide. The methods of the invention can be used to treat cancer, a microbial or parasitic infection, HIV, infection, or a condition assocd. with inflammation, e.g. asthma or rheumatic disease.


IT 389799-47-7 389799-50-2 389799-54-6  
389799-57-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(purine deriv., pyrimidine deriv. or tetrahydroindolone deriv. for treatment of conditions affected by activity of multidrug transporters)


RN 389799-47-7 CAPLUS

CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 389799-57-9 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 7 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 2002:51460 CAPLUS

DN 136:112670

TI Methods using purine derivatives, pyrimidine derivatives, and tetrahydroindolone derivatives for treatment of drug-induced peripheral neuropathy and related conditions

IN Diamond, Jack; Glasky, Alvin J.

PA Neotherapeutics, Inc., USA

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2


*Same as #3:*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004448	A2	20020117	WO 2001-US21373	20010706
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002055506	A1	20020509	US 2001-900844	20010706 ✓
	US 2002061899	A1	20020523	US 2001-899901	20010706 ✓
PRAI	US 2000-216844P	P	20000707		
OS	MARPAT 136:112670				
AB	A method of treating drug-induced peripheral neuropathy comprises administering to a patient with drug-induced peripheral neuropathy an effective quantity of a purine deriv. or analog, a tetrahydroindolone deriv. or analog, or a pyrimidine deriv. or analog. If the compd. is a purine deriv., the purine moiety can be guanine or hypoxanthine. The compd. can induce peripheral nerve sprouting through the action of a neurotrophic factor such as nerve growth factor (NGF) without the occurrence of hyperalgesia. The peripheral nerve sprouting can be nociceptive nerve sprouting. The drug-induced peripheral neuropathy can be drug-induced peripheral neuropathy assocd. with the administration of oncolytic drugs, such as a vinca alkaloid, cisplatin, paclitaxel, suramin, altretamine, carboplatin, chlorambucil, cytarabine, dacarbazine, docetaxel, etoposide, fludarabine, ifosfamide with mesna, tamoxifen, teniposide, or thioguanine. The methods of the invention are particularly useful in treating peripheral neuropathy assocd. with the administration of vincristine, paclitaxel, or cisplatin.				
IT	389799-47-7 389799-50-2 389799-54-6 389799-57-9				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (purine derivs., pyrimidine derivs., and tetrahydroindolone derivs. for treatment of drug-induced peripheral neuropathy and related conditions)				
RN	389799-47-7 CAPLUS				
CN	Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)				




RN 389799-50-2 CAPLUS

CN Benzoic acid, 4-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 389799-54-6 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 389799-57-9 CAPLUS

CN Benzoic acid, 3-[[3-[(2-amino-6-chloro-4-pyrimidinyl)amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 8 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 2001:345113 CAPLUS  
 DN 135:12332  
 TI N-(2-Amino-1,6-dihydro-5-nitroso-6-oxopyrimidin-4-yl)-L-isoleucine-  
 water(4/1): interplay of molecular and supramolecular structures  
 AU Low, John N.; Cannon, Debbie; Quesada, Antonio; Marchal, Antonio;  
 Melguizo, Manuel; Nogueras, Manuel; Sanchez, Adolfo; Glidewell,  
 Christopher  
 CS Department of Chemistry, University of Aberdeen, Meston Walk, Old  
 Aberdeen, AB24 3UE, UK  
 SO Acta Crystallographica, Section C: Crystal Structure Communications  
 (2001), C57(5), 604-607  
 CODEN: ACSCEE; ISSN: 0108-2701  
 PB Munksgaard International Publishers Ltd.  
 DT Journal  
 LA English  
 AB In the title compd., 2C10H15N5O4.cntdot.0.5H2O, there are two independent  
 mols. of the pyrimidinylisoleucine in general positions and a H2O mol.  
 lying on a 2-fold rotation axis. The bond lengths within the org.  
 moieties demonstrate significant polarization of the electronic structure.  
 Each of the org. mols. participates in 12 intermol. H bonds, of O-H...O  
 and N-H...O types, while the H2O mol. acts as a double donor and as a  
 double acceptor of O-H...O H bonds. The org. components are linked by the  
 H bonds into a single three-dimensional framework, reinforced by the H2O  
 mols. Crystallog. data are given.  
 IT 340993-79-5  
 RL: PRP (Properties)  
 (prepn. and crystal structure)  
 RN 340993-79-5 CAPLUS  
 CN L-Isoleucine, N-(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)-,  
 hydrate (4:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 1/4 H2O

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L16 ANSWER 9 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 2000:84798 CAPLUS  
 DN 132:137383  
 TI Preparation of pyrazole derivatives as antitumor agents  
 IN Ejima, Akio; Ohsuki, Satoru; Ohki, Hitoshi; Naito, Hiroyuki; Makino, Chie  
 PA Daiichi Pharmaceutical Co., Ltd., Japan  
 SO PCT Int. Appl., 189 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005230	A1	20000203	WO 1999-JP3962	19990723
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9948002	A1	20000214	AU 1999-48002	19990723
	EP 1103551	A1	20010530	EP 1999-931515	19990723
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2000169475	A2	20000620	JP 1999-211211	19990726
	NO 2001000405	A	20010322	NO 2001-405	20010123
PRAI	JP 1998-208807	A	19980724		
	JP 1998-274459	A	19980929		
	WO 1999-JP3962	W	19990723		

OS MARPAT 132:137383

AB The title compds. I [R1 = H, halo, etc.; R2 = H, halo, OH, etc.; R3 = H, amino, alkoxy, etc.; R4 = H, halo, alkylamino, etc.; R5 = H, alkyl, etc.; Q = heterocyclic ring, etc.; G = heterocyclic ring (further details on said ring are given)] are prepd. Compds. of this invention in vitro showed IC50 values of 0.6 ng/mL to 35 ng/mL against the growth of lung tumor cells.


IT 256929-34-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of pyrazole derivs. as antitumor agents)

RN 256929-34-7 CAPLUS


CN Glycine, N-[2-amino-6-[4-[(1E)-3-[4-(3,5-difluorophenyl)-1-piperazinyl]-1-propenyl]-5-methyl-1H-pyrazol-1-yl]-4-pyrimidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● HCl

L16 ANSWER 10 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1994:435156 CAPLUS  
 DN 121:35156  
 TI Cyclodehydration of 5-[(Carboxymethyl)amino]pyrimidines. Synthesis and Characterization of Novel Mesoionic Imidazo[1,2-c]pyrimidin-3-ones  
 AU Edstrom, Eric D.; Wei, Yuan; Gordon, Michelle  
 CS Department of Chemistry and Biochemistry, Utah State University, Logan, UT, 84322-0300, USA  
 SO Journal of Organic Chemistry (1994), 59(9), 2473-81  
 CODEN: JOCEAH; ISSN: 0022-3263  
 DT Journal  
 LA English  
 AB The cyclodehydration of 5-(carboxymethyl)amino-substituted pyrimidines I (R1 = SMe, NH2) using acid anhydrides provided a general prepn. of novel mesoionic imidazo[1,2-c]pyrimidin-3-one compds., for example II (same R1). Compds. lacking a blocking group at N-1 undergo clean alkylation at this position, under basic reaction conditions, with substituted alkyl chlorides. Imidazo[1,2-c]pyrimidin-3-ones having a benzyl group at N-1 were found to undergo substitution reactions on the pyrimidine ring in the presence of basic nucleophiles. Thus, replacement of a 5-methylthio over a 7-chloro substituent was favored, whereas the 7-chloro group was substituted in compds. where a 5-amino substituent was present. Exposure of imidazo[1,2-c]pyrimidin-3-ones to aq. acid results in the ring opening of the 5-membered ring with loss of CO2 in an overall net reversion of the cyclodehydration reaction. Examn. of the x-ray structures obtained for some II indicated that the 5-membered ring was not arom., but rather a combination of a ring-opened valence tautomer and a charge-delocalized resonance hybrid structure.  
 IT **155670-18-1P 155670-23-8P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as intermediate for imidazo[1,2-c]pyrimidinone resonance hybrid)  
 RN 155670-18-1 CAPLUS  
 CN Glycine, N-(2-amino-6-chloro-4-pyrimidinyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 155670-23-8 CAPLUS  
 CN Glycine, N-(2-amino-6-chloro-4-pyrimidinyl)- (9CI) (CA INDEX NAME)



L16 ANSWER 11 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1993:234397 CAPLUS

DN 118:234397

TI Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase

AU Chern, Ji Wang; Lee, Horng Yuh; Chen, Chien Shu; Shewach, Donna S.; Daddona, Peter E.; Townsend, Leroy B.

CS Med. Lab., Natl. Def. Med. Cent., Taipei, 100, Taiwan

SO Journal of Medicinal Chemistry (1993), 36(8), 1024-31

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English


AB In an effort to develop potent human purine nucleoside phosphorylase (PNP) inhibitors as immunosuppressive and chemotherapeutic agents, several 8-aminoguanine derivs., e.g. I [R = (CH<sub>2</sub>)<sub>5</sub>Me, (CH<sub>2</sub>)<sub>5</sub>CO<sub>2</sub>H, R<sub>1</sub>-R<sub>3</sub>, R<sub>4</sub> = OH, SPh (II), R<sub>5</sub> = iodo, COC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>F-4], and formycin derivs. III (R<sub>6</sub> = SPh, COC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>F-4), were synthesized and evaluated as potential PNP inhibitors. These studies were designed to investigate the hydrophobic effect of a substituent on the N-9 of the purine heterocycle and/or the C-5' positions. The affinity of these compds. to erythrocytic PNP was detd. and none of these compds. showed a better affinity than those of the parent compds. The effect of hydrophobicity at the N-9 and the C-5' positions might play an important role in binding to the active site of PNP. Thus, compd. II was found to be the best inhibitor in this series.

IT 146203-16-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and ring closure of)

RN 146203-16-9 CAPLUS

CN Hexanoic acid, 6-[[2-amino-1,6-dihydro-5-[[[(methoxycarbonyl)amino]thioxomethyl]amino]-6-oxo-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 12 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1991:675113 CAPLUS

DN 115:275113

TI A novel theory of tripartate conjugate and its application to synthesize soluble macromolecular conjugates

AU Bhattacharyya, A.

CS Div. Biochem. Eng., Indian Inst. Chem. Biol., Calcutta, 700 032, India

SO Journal of the Indian Chemical Society (1991), 68(3), 172-4

CODEN: JICSAH; ISSN: 0019-4522

DT Journal

LA English

AB A scheme was designed by which a tripartite conjugate can be constructed. The conjugate is designed as a ligand-bridge-protein. The insol. org. compd. (ligand) is coupled to a macromol. (protein) via a very hydrophilic water-sol. mol. (bridge). It was found that citric acid can be an effective bridge.


IT 137682-09-8P

RL: PREP (Preparation)

(prepn. and conjugation with albumin)

RN 137682-09-8 CAPLUS

CN Butanedioic acid, 2-[2-[[2-amino-5-(4-chlorophenyl)-6-ethyl-4-pyrimidinyl]amino]-2-oxoethyl]-2-hydroxy- (9CI) (CA INDEX NAME)



2


IT 137682-09-8DP, albumin conjugates

RL: PREP (Preparation)

(prepn. of)

RN 137682-09-8 CAPLUS

CN Butanedioic acid, 2-[2-[[2-amino-5-(4-chlorophenyl)-6-ethyl-4-pyrimidinyl]amino]-2-oxoethyl]-2-hydroxy- (9CI) (CA INDEX NAME)



L16 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1990:591849 CAPLUS  
 DN 113:191849  
 TI Isosteric oligonucleotide analogs containing sulfur  
 IN Benner, Steven Albert  
 PA Switz.  
 SO PCT Int. Appl., 88 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8912060	A1	19891214	WO 1989-US2323	19890526
	W: AU, JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 5216141	A	19930601	US 1988-202528	19880606
	AU 8937654	A1	19900105	AU 1989-37654	19890526
	AU 635209	B2	19930318		
	EP 418309	A1	19910327	EP 1989-906936	19890526
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 03505452	T2	19911128	JP 1989-506581	19890526
PRAI	US 1988-202528	A	19880606		
	WO 1989-US2323	A	19890526		

AB Oligonucleotides contg. isosteric S linkages instead of a phosphate, e.g. I, which are resistant to chem. and in vivo enzymic degrdn., lipophilic, and thereby easily cross biol. barriers, and thus useful as, e.g. probes for cDNA, can be prepd. from rigid or flexible isosteric building blocks [II, III, and IV; X = O, CH<sub>2</sub>; R = OH, R<sub>1</sub> = SH; or R = SH, R<sub>1</sub> = OH; B = heterocycle ring selected from (aza)pyrimidine, (aza)purine, pyrrolopyrimidine, pyrazolopyrimidine, triazolopyrimidine, imidazolopyrimidine, pyrrolopyridine, pyrazolopyridine, and triazolopyridine, which may be functionalized with NH<sub>2</sub>, HO, halo, acylamino, or acylhydroxy]. Thus, ozonolysis of 2-(pivaloyloxymethyl)cyclohex-4-enol (V; R<sub>3</sub> = pivaloyl) (prepn. given) in MeOH and treatment of the resulting 3,4-trans-1-methoxy-3-pivaloyloxymethyl-4-(2'-hydroxyethyl)tetrahydrofuran with Dowex W50 in refluxing PhMe gave a 2,8-dioxo[1.2.3]bicyclooctane (VI) which was stirred 15 h at room temp. with bis(trimethylsilyloxy)pyrimidine in the presence of CF<sub>3</sub>SO<sub>3</sub>SiMe<sub>3</sub> in MeCN to give II (X = O, R = OH, R<sub>1</sub> = pivaloyloxy, B = 1-uracilyl). Reaction of the latter with EtO<sub>2</sub>CN:NCO<sub>2</sub>Et, Ph<sub>3</sub>P, and AcSH in THF gave II (X = O, R = SAc, R<sub>1</sub> = pivaloyloxy, B = 1-uracilyl) which could be conveniently stored and deprotected immediately prior to condensation, by redn. with LiBET<sub>3</sub>H (super-hydride) in THF to give a bishomonucleoside II (X = O, R = SH, R<sub>1</sub> = OH, B = 1-uracilyl). No synthetic examples for I or other oligonucleotides but only synthetic schemes were given. I bind to complementary A-C-C-T-C-C-T (no data).


IT 128435-43-8P 128435-44-9P 128453-43-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as intermediate for acyclic nucleoside analog)

RN 128435-43-8 CAPLUS

CN Butanoic acid, 4,4'-dithiobis[2-[(2-amino-6-chloro-4-pyrimidinyl)amino]-, dimethyl ester, [S-(R\*,R\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 128435-44-9 CAPLUS

CN Butanoic acid, 4,4'-dithiobis[2-[(2,5-diamino-6-chloro-4-pyrimidinyl)amino]-, dimethyl ester, [S-(R\*,R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 128453-43-0 CAPLUS

CN Butanoic acid, 4,4'-dithiobis[2-[[2-amino-6-chloro-5-[(4-chlorophenyl)azo]-4-pyrimidinyl]amino]-, dimethyl ester, [S-(R\*,R\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.

PAGE 1-A



PAGE 1-B





L16 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1990:139840 CAPLUS  
 DN 112:139840  
 TI Preparation of new peptides as antiviral agents  
 IN Marumoto, Ryuji; Fukuda, Tsunehiko  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 10 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01226899	A2	19890911	JP 1988-54651	19880308
PRAI	JP 1988-54651		19880308		

OS MARPAT 112:139840

AB H(NHCHR2CO)l(NHCHR1CONHCHR2CO)m(NHCHR1CO)nOH [R1 = L- or D-.omega.-nucleo-.alpha.-amino acid residue; R2 = L- or D-.alpha.-amino acid residue except .omega.-nucleo-.alpha.-amino acid residue; l, n = 0, 1; m .gtoreq.1 integer], useful as antivirals, esp. useful as inhibitors for HBV virus, and for diagnosis of sicklemlia, Down's syndrome, and hepatitis (no data), are prepd. H-L-Ser-(L-willardine)-L-Ser-(L-willardine)-L-Ser-(L-9-adenylalanine)-L-Ser-L-willardine)-L-Ser-(L-9-adenylalanine)-Gly-OH was prepd. using a automated peptide synthesizer by condensing amino acid units such as adenyaminopropionic acid deriv. I (prepn. given).


IT 125883-42-3P 125883-43-4P 125883-45-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in prepn. of antiviral peptide)


RN 125883-42-3 CAPLUS

CN Butanoic acid, 2-amino-4-[(2-amino-6-chloro-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



RN 125883-43-4 CAPLUS


CN Butanoic acid, 2-amino-4-[(2-amino-6-chloro-5-[(4-chlorophenyl)azo]-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



09/907,273 (subgenus around elected species)


RN 125883-45-6 CAPLUS

CN Butanoic acid, 2-amino-4-[(2,5-diamino-1,6-dihydro-6-oxo-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




L16 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1987:214262 CAPLUS  
 DN 106:214262  
 TI Bridged isocytosine-adenosine compounds: synthesis and antibacterial evaluation  
 AU Lever, O. William, Jr.; Vestal, B. Randall  
 CS Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA  
 SO Journal of Heterocyclic Chemistry (1986), 23(3), 901-3  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DT Journal  
 LA English  
 OS CASREACT 106:214262  
 AB Twelve title compds. I (R = NO, NO<sub>2</sub>; n = 2, 3, 4, 5, 6, 7) were prepd. from the corresponding H<sub>2</sub>N(CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>H by sequential N-benzyloxycarbonylation with PhCH<sub>2</sub>OCOC<sub>2</sub>H<sub>5</sub>, conversion to active esters by treatment with N-hydroxysuccinimide, amidation with 5'-amino-5'-deoxyadenosine, hydrogenolysis to remove the benzyloxycarbonyl group, and coupling with 6-(methylthio)-5-nitrosoisocytosine or 6-chloro-5-nitroisocytosine. I showed no significant antibacterial activity when tested in vitro against 22 bacterial strains at 30 .mu.g/mL.  
 IT 108257-25-6P 108257-26-7P 108257-27-8P  
 108257-28-9P 108257-30-3P 108257-31-4P  
 108257-32-5P 108257-33-6P 108282-48-0P  
 108318-63-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 108257-25-6 CAPLUS  
 CN Adenosine, 5'-[[3-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxopropyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 108257-26-7 CAPLUS  
 CN Adenosine, 5'-[[4-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxobutyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-27-8 CAPLUS

CN Adenosine, 5'-[[6-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxohexyl]amino]-5'-deoxy- (9CI) . (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-28-9 CAPLUS

CN Adenosine, 5'-[[7-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxoheptyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-30-3 CAPLUS

CN Adenosine, 5'-[[3-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxopropyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-31-4 CAPLUS

CN Adenosine, 5'-[[4-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxobutyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-32-5 CAPLUS

CN Adenosine, 5'-[[5-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxopentyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108257-33-6 CAPLUS

CN Adenosine, 5'-[[7-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxoheptyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 108282-48-0 CAPLUS

CN Adenosine, 5'-[[5-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]-1-oxopentyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 108318-63-4 CAPLUS

CN Adenosine, 5'-[[6-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-1-oxohexyl]amino]-5'-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L16 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1986:207022 CAPLUS  
 DN 104:207022  
 TI Specific inhibitors in vitamin biosyntheses. Part 8. Syntheses of some functionalized 7,7-dialkyl-7,8-dihydropterins  
 AU Cameron, Robert; Nicholson, Sydney H.; Robinson, David H.; Suckling, Colin J.; Wood, Hamish C. S.  
 CS Dep. Pure Appl. Chem., Univ. Strathclyde, Glasgow, G1 1XL, UK  
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1985), (10), 2133-43  
 CODEN: JCPRB4; ISSN: 0300-922X  
 DT Journal  
 LA English  
 OS CASREACT 104:207022  
 AB The functionalized blocked 7,8-dihydropteridines I (R = OH, R1 = 4-ClC6H4CH2; R = H, R1 = OH, CH2CO2H; R = 2,4,5-Cl3C6H2O, R1 = H) and II were prep'd. The functional groups were chosen to provide compds. with potential for investigating the protein chem. of enzymes in the pathway leading to dihydrofolate and, in particular, of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase. The potential of 7-substituents to provide sites of attachment of inhibitors to columns for affinity chromatog. was explored but the extent of the study was curtailed by the restricted applicability of NOCl addn. to alkenes, a reaction used in the synthesis of precursors for I and II. I (R = 2,4,5-Cl3C6H2O, R1 = H) and II were designed to have enhanced transport properties.  
 IT 102222-95-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and cyclization of)  
 RN 102222-95-7 CAPLUS  
 CN Hexanoic acid, 4-[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]-4-methyl-5-oxo- (9CI) (CA INDEX NAME)






L16 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1983:605528 CAPLUS  
 DN 99:205528  
 TI Minoxidil sulfate, a metabolite of minoxidil  
 AU Johnson, Garland A.; Barsuhn, Karen J.; McCall, John M.  
 CS Cardiovasc. Dis. Res. Cent. Nerv. Syst. Dis. Res., Upjohn Co., Kalamazoo, MI, USA  
 SO Drug Metabolism and Disposition (1983), 11(5), 507-8  
 CODEN: DMDSAI; ISSN: 0090-9556  
 DT Journal  
 LA English  
 AB Following the i.v. administration of labeled minoxidil (I) [38304-91-5] to rats, reversed-phase high-pressure liq. chromatog. of bile of I-treated rats confirmed the presence of known I-metabolites as well as a previously unknown metabolite, minoxidil sulfate [83701-22-8]. Minoxidil sulfate comprised a small portion of the total radioactivity in the bile, i.e. 3% of the total, and it produced a distinct peak in the profile of biliary I metabolites.  
 IT 56828-38-7  
 RL: BIOL (Biological study)  
 (as minoxidil metabolite)  
 RN 56828-38-7 CAPLUS  
 CN Pentanoic acid, 5-[(2,6-diamino-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1983:437986 CAPLUS  
 DN 99:37986  
 TI Detection of C-nitroso dimer formation by field desorption mass spectrometry  
 AU Johnson, R. L.; Lever, O. W., Jr.; Brent, D. A.  
 CS Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA  
 SO Organic Mass Spectrometry (1983), 18(1), 36-41  
 CODEN: ORMSBG; ISSN: 0030-493X  
 DT Journal  
 LA English  
 AB Field desorption mass spectrometry showed Me<sub>2</sub>CClCH(NO)CH<sub>2</sub>OR (R = cyclohexyl, PhCH<sub>2</sub>, Me, cyclopentyl) (I-IV, resp.) to exist as dimers whereas p-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>NHPh and pyrimidines V [R = Me, (CH<sub>2</sub>)<sub>5</sub>CO<sub>2</sub>H] are monomeric. Mixed dimers of II with I, III, and IV and I with IV were also obsd. using the technique.  
 IT 86296-76-6  
 RL: PRP (Properties)  
 (mass spectrum of, field desorption)  
 RN 86296-76-6 CAPLUS  
 CN Hexanoic acid, 6-[(2-amino-1,6-dihydro-5-nitroso-6-oxo-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1979:137759 CAPLUS

DN 90:137759

TI The reaction of 2,4-diamino-6-piperidinopyrimidine 3-oxide with acid anhydrides

AU McCall, John M.; TenBrink, Ruth E.; Royer, Max E.; Ko, Howard

CS Res. Lab., Upjohn Co., Kalamazoo, MI, USA

SO Journal of Heterocyclic Chemistry (1978), 15(8), 1529-30

CODEN: JHTCAD; ISSN: 0022-152X

DT Journal

LA English


AB Reaction of the title compd. I (R = R1 = H) with 1 equiv. of Ac2O gave 26:1 I (R = Ac, R1 = H) and I (R = H, R1 = Ac). Bz2O reacted similarly to give a 16:1 ratio of the corresponding amides. Excess anhydrides gave the diamides. Reaction of I (R = R1 = H) with glutaric anhydride gave only I (R = CO(CH2)3CO2H, R1 = H).

IT 69729-67-5P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 69729-67-5 CAPLUS

CN Pentanoic acid, 5-[[2-amino-3-oxido-6-(1-piperidinyl)-4-pyrimidinyl]amino]-5-oxo-, methyl ester (9CI) (CA INDEX NAME)




L16 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1977:593445 CAPLUS  
 DN 87:193445  
 TI Radioimmunoassay of minoxidil in human serum  
 AU Royer, Max E.; Ko, Howard; Gilbertson, Terry J.; McCall, John M.; Johnston, Karen T.; Stryd, Ronald  
 CS Drug Metab. Res. Sect., Upjohn Co., Kalamazoo, MI, USA  
 SO Journal of Pharmaceutical Sciences (1977), 66(9), 1266-9  
 CODEN: JPMSAE; ISSN: 0022-3549  
 DT Journal  
 LA English  
 AB A simple, sensitive, and specific radioimmunoassay for detg. minoxidil (I) [38304-91-5] was developed. Rabbit antiserum to 2 I haptens were compared for cross-reactivity and assay levels on human serums. One antiserum had little cross-reactivity with I metabolites. The radioimmunoassay is specific for detg. I directly in serum without extn. Human serum I levels were detd. from a single oral dose. The limit of detection was 3.02 ng/mL.  
 IT **64675-16-7P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and immune cross-reactions of, with minoxidil)  
 RN 64675-16-7 CAPLUS  
 CN Pentanoic acid, 5-[[2-amino-3-oxido-6-(1-piperidinyl)-4-pyrimidinyl]amino]-5-oxo- (9CI) (CA INDEX NAME)




L16 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1977:453368 CAPLUS  
 DN 87:53368  
 TI 2,4-Diaminopyrimidine derivatives  
 PA Fabrica Espanola de Productos Quimicos y Farmaceuticos S. A., Spain  
 SO Span., 9 pp.  
 CODEN: SPXXAD  
 DT Patent  
 LA Spanish  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ES 431918	A1	19761101	ES 1974-431918	19741114
PRAI	ES 1974-431918		19741114		
AB	Amides I (R = H, X = o-C <sub>6</sub> H <sub>4</sub> ; R = 3,4,5-(MeO) <sub>3</sub> C <sub>6</sub> H <sub>2</sub> CH <sub>2</sub> , X = CH:CH, CH <sub>2</sub> CH <sub>2</sub> ) were prepd. by acylating 2,4-pyrimidinediamines with the appropriate anhydrides.				
IT	<b>63271-78-3P 63306-49-0P</b>				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	63271-78-3 CAPLUS				
CN	Butanoic acid, 4-[[2-amino-5-[(3,4,5-trimethoxyphenyl)methyl]-4-pyrimidinyl]amino]-4-oxo- (9CI) (CA INDEX NAME)				



RN 63306-49-0 CAPLUS  
 CN 2-Butenoic acid, 4-[[2-amino-5-[(3,4,5-trimethoxyphenyl)methyl]-4-pyrimidinyl]amino]-4-oxo-, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L16 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1977:189996 CAPLUS  
 DN 86:189996  
 TI 2-Amino-4-(carboxyacetylamido)pyrimidine bismuth salts  
 PA Fabrica Espanola de Productos Quimicos y Farmaceuticos S. A., Spain  
 SO Span., 8 pp.  
 CODEN: SPXXAD  
 DT Patent  
 LA Spanish  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ES 432523	A1	19760901	ES 1974-432523	19741203
PRAI	ES 1974-432523		19741203		

AB The pyrimidine compds. I (R = H, PhCH<sub>2</sub> or methoxybenzyl; Z = alkylene, arylene) were converted into the Bi salts by treatment with yellow Bi oxide, freshly prep'd. from Bi(NO<sub>3</sub>)<sub>3</sub> and aq. NaOH, in a solvent or mixt. of solvents of 10 .mu. polarity. Thus, a mixt. of I [R = H, Z = (CH<sub>2</sub>)<sub>3</sub>] and Bi oxide in 210 L n-hexane and 1.5 L H<sub>2</sub>O was stored at 65.degree.C for <10 h to give the Bi salt. Also prep'd. was the Bi salt of I [R = 3,4,5-(MeO)<sub>3</sub>C<sub>6</sub>H<sub>2</sub>, Z = (CH<sub>2</sub>)<sub>2</sub>].

IT **62668-05-7**  
 RL: PROC (Process)  
 (conversion of, to bismuth salt)

RN 62668-05-7 CAPLUS


CN Pentanoic acid, 5-[(2-amino-4-pyrimidinyl)amino]-5-oxo- (9CI) (CA INDEX NAME)



IT **62668-06-8P 62668-08-0P**  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)

RN 62668-06-8 CAPLUS


CN Pentanoic acid, 5-[(2-amino-4-pyrimidinyl)amino]-5-oxo-, bismuth salt (9CI) (CA INDEX NAME)



●x Bi(x)

RN 62668-08-0 CAPLUS

CN Butanoic acid, 4-[[2-amino-5-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]-4-oxo-, bismuth salt (9CI) (CA INDEX NAME)




●x Bi(x)

IT 62668-07-9

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with pyrimidinediamine carboxyacetyl derivs.)

RN 62668-07-9 CAPLUS

CN Butanoic acid, 4-[[2-amino-5-(3,4,5-trimethoxyphenyl)-4-pyrimidinyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



L16 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1977:189848 CAPLUS

DN 86:189848

TI Synthesis of compounds related to antitumor agents. V. On the reaction of aliphatic carboxylates with 2,4-diamino-5-hydroxy-6-methylpyrimidine

AU Kato, Tetsuo; Oda, Noriichi; Ito, Isoo

CS Fac. Pharm. Sci., Nagoya City Univ., Nagoya, Japan

SO Chemical & Pharmaceutical Bulletin (1977), 25(3), 491-4

CODEN: CPBTAL; ISSN: 0009-2363

DT Journal

LA English

AB 2,4-Diamino-5-hydroxy-6-methylpyrimidine (I) was treated with  $\text{CH}_2(\text{CO}_2\text{Et})_2$  at 140-50.degree. to give pyrimidine II ( $\text{R} = \text{OH}$ ,  $\text{R}_1 = \text{OEt}$ ,  $\text{R}_2 = \text{CH}_2\text{CO}_2\text{Et}$ ) which was treated with  $\text{HOAc}$  at 40-50.degree. for 10 min to give a mixt. of pyrimido[5,4-d][1,4]oxazepine III ( $\text{R}_3 = \text{OH}$ ,  $\text{R}_4 = \text{OEt}$ ,  $\text{R}_5 = \text{Ac}$ ) (IV) and dihydrooxazolo[4,5-d]pyrimidine V. IV was refluxed in EtOH for 8 h to give III ( $\text{R}_3\text{R}_4 = \text{O}$ ,  $\text{R}_5 = \text{Ac}$ ) which was deacetylated and lactone-cleaved by hydrolysis with 10%  $\text{HCl}$ . The resulting hydroxy acid deriv. was cyclized in  $\text{Me}_2\text{SO}$  at 140-150.degree. for 20 min. to give III ( $\text{R}_3\text{R}_4 = \text{O}$ ,  $\text{R}_5 = \text{H}$ ). Pyrimido[5,4-b]oxazine VI, oxazolo[4,5-d]pyrimidine VII, and II [ $\text{RR}_1 = \text{O}$ ,  $\text{R}_2 = \text{CH}_2\text{CH}_2\text{CO}_2\text{R}_6$  ( $\text{R}_6 = \text{Me}$ ,  $\text{Et}$ )] were also prepd. from I.


IT 62812-12-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and lactonization of)

RN 62812-12-8 CAPLUS

CN Propanoic acid, 3-[(2-amino-5-hydroxy-6-methyl-4-pyrimidinyl)amino]-3-oxo- (9CI) (CA INDEX NAME)





L16 ANSWER 24 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1975:588142 CAPLUS

DN 83:188142

TI Metabolism of minoxidil, a new hypotensive agent. II. Biotransformation following oral administration to rats, dogs, and monkeys

AU Thomas, Richard C.; Harpootlian, Harry

CS Res. Lab., Upjohn Co., Kalamazoo, MI, USA

SO Journal of Pharmaceutical Sciences (1975), 64(8), 1366-71

CODEN: JPMSAE; ISSN: 0022-3549

DT Journal

LA English

AB The biotransformation of minoxidil (I) [38304-91-5] was studied in the rat, dog, and monkey and compared to reported results in the human. Each species excreted substantially the same metabolites, but in quite different relative amts. The monkey and the human exhibited similar metabolite profiles, whereas the dog and rat were quant. different from each other and from the monkey and human. The major excretory product for the monkey and human was I glucuronide [56828-40-1]. Substantially smaller amts. of unchanged I, 2,4-diamino-6-(4'-hydroxypiperidino)pyrimidine 3-oxide [56828-37-6], and more polar metabolites also were excreted by these 2 species. The major excretory product in the rat was unchanged I. Almost as much (combined) of the 2 acidic metabolites, 2,4-diamino-6-(4'-carboxy-n-butylamino)pyrimidine [56828-38-7] and its 3-oxide [56828-41-2], also were produced. Smaller amts. of the glucuronide of I, 2,4-diamino-6-(4'-hydroxypiperidino)pyrimidine 3-oxide, its 3'-hydroxy isomer [56828-39-8], and 2,4-diamino-6-piperidinopyrimidine [24867-26-3] also were excreted by the rat. The major metabolite of I excreted by the dog was the 4'-hydroxy metabolite. Smaller amts. of unchanged I and polar metabolites and much smaller amts. of the glucuronide of I, the 3'-hydroxy metabolite, and 2,4-diamino-6-piperidinopyrimidine also were excreted by the dog. Evidence was obtained for a 4'-hydroxy metabolite glucuronide in this species. The major circulatory material in dog plasma was the 4'-hydroxy metabolite, whereas it was the glucuronide of I in monkey plasma.


IT 56828-38-7 56828-41-2

RL: BIOL (Biological study)

(as minoxidil metabolite, species in relation to)

RN 56828-38-7 CAPLUS


CN Pentanoic acid, 5-[(2,6-diamino-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




Same as #17

RN 56828-41-2 CAPLUS


CN Pentanoic acid, 5-[(2,6-diamino-1-oxido-4-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




L16 ANSWER 25 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1975:38479 CAPLUS  
 DN 82:38479  
 TI Synthesis and antifolate activity of isoaminopterin  
 AU Nair, M. G.; Mercer, L. P.; Baugh, Charles M.  
 CS Dep. Biochem., Univ. South Alabama, Mobile, AL, USA  
 SO Journal of Medicinal Chemistry (1974), 17(12), 1268-72  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 AB Isoaminopterin (I) [53661-94-2], a candidate antitumor agent, inhibited growth of folate-requiring *Lactobacillus casei* and *Streptococcus faecium* at ED50 0.90 .times. 10<sup>-13</sup> and 45 .times. 10<sup>-13</sup>M, resp., and inhibited dihydrofolate reductase [9002-03-3] from *L. casei* by 50% at 14.5 .times. 10<sup>-9</sup>M. These were similar to the effective concns. of methotrexate [59-05-2]. I was prepd. by a modification of the isofolic acid synthesis by W. R. Boon and T. Leigh (1951), or by an alternate procedure involving coupling of 6-chloro-2,4-diaminopteridine [17714-06-6] with .alpha.-amino-p-toluic acid [56-91-7].  
 IT **53661-96-4**  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (cyclization of)  
 RN 53661-96-4 CAPLUS  
 CN Benzoic acid, 4-[[[(2,5,6-triamino-4-pyrimidinyl)amino]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




IT **53661-95-3P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and redn. of)  
 RN 53661-95-3 CAPLUS  
 CN Benzoic acid, 4-[[[(2,6-diamino-5-nitro-4-pyrimidinyl)amino]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




L16 ANSWER 26 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1974:146111 CAPLUS  
 DN 80:146111  
 TI Pteridines. LX. Synthesis and autoxidation of 7,8-dihydroxanthopterins  
 AU Pfeleiderer, Wolfgang  
 CS Fachbereich Chem., Univ. Konstanz, Constance, Fed. Rep. Ger.  
 SO Chemische Berichte (1974), 107(3), 785-95  
 CODEN: CHBEAM; ISSN: 0009-2940  
 DT Journal  
 LA German  
 AB Reaction of the chloropyrimidines I with R3NHCR4R5CO2Et and ring closure of the resulting aminopyrimidines II gave the title xanthopterins III (R1-R5 = H or Me, R6 = H). Similarly prepd. was III (R1-R5 = H, R6 = Me). The pKa values and uv spectra were detd. The monoanions of III were subject to autoxidn., which was catalyzed by NH3 and primary angles.  
 IT 1154-85-4P 14508-66-8P 14699-57-1P  
 52296-01-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of)  
 RN 1154-85-4 CAPLUS  
 CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14508-66-8 CAPLUS  
 CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 14699-57-1 CAPLUS  
 CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 52296-01-2 CAPLUS

CN L-Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 27 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1974:128131 CAPLUS  
 DN 80:128131  
 TI Synthesis and biological evaluation of isofolic acid  
 AU Nair, M. G.; Baugh, Charles M.  
 CS Nutr. Program, Univ. Alabama, Birmingham, AL, USA  
 SO Journal of Medicinal Chemistry (1974), 117(2), 223-6  
 CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 AB Isofolic acid (I) [52560-13-1] was prepd. by displacement reaction of N-glycyl-.alpha.-amino-p-toluic acid [51542-05-3] with 2-amino-6-chloro-5-nitro-4(3H)-pyrimidinone [1007-99-4], dithionite redn. of the nitro group, thermal cyclization, and MnO<sub>2</sub> oxidn. to isopteroic acid (II) [51542-06-4], which was coupled with di-Et glutamate by the mixed anhydride method. I and II were comparable to methotrexate [59-05-2] as inhibitors of Streptococcus faecium, while Lactobacillus casei was inhibited by I but not by II. The implications of the use of II as a specific inhibitor of organisms capable of attaching the terminal glutamyl moiety to the mol. were discussed.  
 IT 52121-32-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 52121-32-1 CAPLUS  
 CN Benzoic acid, 4-[[[(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)amino]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




IT 52121-33-2  
 RL: RCT (Reactant); RACT (Reactant or reagent) (thermal cyclization of)  
 RN 52121-33-2 CAPLUS  
 CN Benzoic acid, 4-[[[(2,5-diamino-1,6-dihydro-6-oxo-4-pyrimidinyl)amino]acetyl]amino]methyl]- (9CI) (CA INDEX NAME)




L16 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1974:37077 CAPLUS  
 DN 80:37077  
 TI Synthesis and electrophilic bromination of 2-methyl-9-carbethoxy-1,3,4,7-tetraazacycl[3.3.3]azine  
 AU Ceder, Olof; Rosen, Kenneth  
 CS Chalmers Inst. Technol., Univ. Goteborg, Goteborg, Swed.  
 SO Acta Chemica Scandinavica (1947-1973) (1973), 27(7), 2421-5  
 CODEN: ACSAA4; ISSN: 0001-5393  
 DT Journal  
 LA English  
 AB 1,3,4,7-Tetraazacycl[3.3.3]azine (I, R = H) was prepd. from 2,4-diaminopyrimidine and EtOCH:C(CN)CO<sub>2</sub>Et. Electrophilic bromination of I (R = H) gave I (R = Br).  
 IT **51138-31-9P**  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 51138-31-9 CAPLUS  
 CN 2-Propenoic acid, 3-[(2-amino-4-pyrimidinyl)amino]-2-cyano-, ethyl ester, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



L16 ANSWER 29 OF 40 CAPLUS COPYRIGHT 2003 ACS  
 AN 1967:85762 CAPLUS  
 DN 66:85762  
 TI Synthesis of some N-methylated pteridines related to 7,8-dihydroxanthopterin  
 AU Zondler, Helmut; Forrest, Hugh S.; Lagowski, Jeanne M.  
 CS Univ. of Texas, Austin, TX, USA  
 SO Journal of Heterocyclic Chemistry (1967), 4(1), 12-15  
 CODEN: JHTCAD; ISSN: 0022-152X  
 DT Journal  
 LA English  
 AB Seven methylated pteridines were synthesized by condensation of a 4-chloro-5-nitropyrimidine with a .beta.-oxoamine (or a blocked deriv.), redn. of the nitro group, and subsequent ring closure. This scheme provides a new route to dihydroxanthopterin (I). Several cases are reported, however, in the uracil series where ring closure could not be effected.  
 IT **14508-66-8P 14699-57-1P**  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 14508-66-8 CAPLUS  
 CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14699-57-1 CAPLUS  
 CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)





L16 ANSWER 30 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1965:29707 CAPLUS

DN 62:29707

OREF 62:5278h,5279a-b

TI Pteridine derivatives. IX. 2,6-Diamino-4-hydroxypteridine and related dihydropteridines

AU Stuart, Alexander; West, D. W.; Wood, H. C. S.

CS Roy. Coll. Sci. Technol., Glasgow, UK

SO J. Chem. Soc. (1964), (Dec.), 4769-74

DT Journal


LA English

AB cf CA 55, 11422i. An unambiguous synthesis of 2,6-diamino-4-hydroxypteridine is described and the product is shown to be identical with a specimen isolated by van Baalen and Forrest (CA 53, 15089a) from blue-green algae. The structure of some related dihydropteridines is examd., and in particular the structure of 7,8-dihydroxanthopterin (I) is confirmed.

IT **1140-88-1**, Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- **1154-85-4**, Alanine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-2-methyl-, ethyl ester **14699-57-1**, Glycine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-, ethyl ester (prepn. of)


RN 1140-88-1 CAPLUS

CN Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- (7CI, 8CI) (CA INDEX NAME)




RN 1154-85-4 CAPLUS

CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14699-57-1 CAPLUS

CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 31 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1965:29706 CAPLUS

DN 62:29706

OREF 62:5278f-h

TI Chemical and kinetic studies on the reaction of 2-hydrazino-3-phenylquinoxaline with carbonyl compounds. I

AU Tagami, Shoichiro; Shiho, Denitsu

CS Univ. Toyama, Japan

SO Yakugaku Zasshi (1964), 84(11), 1085-90

DT Journal


LA Japanese

AB A mixt. of 6.0 g. 2-chloro-3-phenylquinoxaline, 17 g. MeNH<sub>2</sub>.HCl, 13 g. Na<sub>2</sub>CO<sub>3</sub>, and 50 ml. EtOH is heated 7 hrs. in an autoclave at 100-50.degree. to give 5.8 g. 2-methylamino-3-phenylquinoxaline (I), pale yellow needles, m. 132.degree. (dil. MeOH). I (4.8 g.) in 400 ml. H<sub>2</sub>O is treated overnight with 80 ml. concd. HCl and 2.4 g. NaNO<sub>2</sub> and the resulting nitrosoamine compd. (pale yellow needles, m. 109.5.degree. (Me<sub>2</sub>CO)) (1.31 g.) is reduced in 70 ml. Et<sub>2</sub>O by using 20 ml. ethereal soln. of 0.19 g. LiAlH<sub>4</sub> to give 2-(1-methylhydrazino)-3-phenylquinoxaline (II); HCl salt m. 245.degree. (decompn.). II (0.25 g.) is dissolved in a small amt. of EtOH and kept at room temp. with 0.0015 mole aldehyde to give the following III (R and m.p. given): Ph, 181.5.degree.; p-ClC<sub>6</sub>H<sub>4</sub>, 115.degree.; p-NO<sub>2</sub>C<sub>6</sub>H<sub>4</sub>, 171.degree.. Pyrolysis of III gives the corresponding 1-substituted s-triazolo [4,3-a] quinoxaline with concurrent elimination of a hydrocarbon. Factors which apparently govern the elimination of alkyl groups from III are discussed. Also, the kinetic of the pyrolysis reaction are studied and the mechanisms for this type of cleavage presented.

IT 1140-88-1, Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- 1154-85-4, Alanine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-2-methyl-, ethyl ester 14699-57-1, Glycine, N-(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)-, ethyl ester (prepn. of)

RN 1140-88-1 CAPLUS


CN Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- (7CI, 8CI) (CA INDEX NAME)



RN 1154-85-4. CAPLUS


CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)

*Same as #30*



RN 14699-57-1 CAPLUS

CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester  
(9CI) (CA INDEX NAME)



L16 ANSWER 32 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1964:486219 CAPLUS

DN 61:86219

OREF 61:15066h,15067a-c

TI Effect of a number of N-pyrimidyl amino acids and of some of their 5-aryldazo derivatives on the growth of certain microorganisms

AU Roy-Burman, P.; Sen, D.

CS Univ. Coll. Sci. Technol., Calcutta

SO Biochem. Pharmacol. (1964), 13(10), 1437-49

DT Journal


LA Unavailable

AB Sixteen new N-pyrimidyl amino acids were obtained by substitution at the C-2, C-4, or C-6 position of 2,4-diamino-6-methylpyrimidine by aromatic amino acids or different carboxyalkyl amino groups (i.e., aliphatic amino acid moiety). These compds. were tested for their effect on the growth of *Streptococcus faecalis*, *Lactobacillus arabinosus*, and *Escherichia coli*. The new compds., 2,4-diamino-5-aryldazo-6-methylpyrimidine and six N-(5-aryldazo-4-pyrimidyl) amino acids, were also studied. 2,4-Diamino-6-methylpyrimidine inhibited growth of all 3 microorganisms tested, but substitution at the C-2, C-4, or C-6 position by carboxyalkyl amino groups produced compds. with little or no inhibitory effects. The three N-pyrimidyl compds. substituted with aromatic amino acids inhibited growth but were less effective than the parent compd. All the 5-aryldazopyrimidines significantly inhibited growth of *S. faecalis* and, to a lesser extent, *L. arabinosus*. It was observed that among these compds. the inhibitory activity decreased with increase in the bulk of the amino acid moiety. Investigation of the mechanism of the inhibitory action of these compds. in *S. faecalis* revealed that they acted primarily as folic acid antagonists in a manner consistent with an assumption that they interfere with the enzymic conversion of folic acid to N<sup>5</sup>-formyltetrahydrofolic acid in *S. faecalis*.

IT 93727-00-5, Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- 94093-95-5, Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- 94264-54-7, Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylbutyl)amino]-6-methyl-5-pyrimidinyl]azo]- 96063-58-0, Benzoic acid, p-[2-amino-4-[(.alpha.-carboxyphenethyl)amino]-6-methyl-5-pyrimidinyl]azo]- (bactericidal activity of)


RN 93727-00-5 CAPLUS

CN Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 94093-95-5 CAPLUS

CN Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 94264-54-7 CAPLUS

CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)



RN 96063-58-0 CAPLUS


CN Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (7CI) (CA INDEX NAME)



IT 89465-54-3, Glycine, N-(2,6-diamino-4-pyrimidinyl)-  
 89897-36-9, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-  
 90198-25-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-  
 90198-46-2, Serine, N-(2-amino-6-methyl-4-pyrimidinyl)-  
 90649-20-0, Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- 91253-20-2, Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- 91253-21-3, Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- 91717-29-2, Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- 92296-32-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl-  
 (prepn. and bactericidal activity of)


RN 89465-54-3 CAPLUS

CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 89897-36-9 CAPLUS

CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-25-7 CAPLUS

CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-46-2 CAPLUS

CN Serine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90649-20-0 CAPLUS

CN Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)




RN 91253-20-2 CAPLUS

CN Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 91253-21-3 CAPLUS

CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 91717-29-2 CAPLUS


CN Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 92296-32-7 CAPLUS

CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA INDEX NAME)





L16 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1964:60902 CAPLUS

DN 60:60902

OREF 60:10680g-h,10681a-b

TI Pyrimidines. IV. Derivatives of 2-amino-4-methyl-6-hydroxypyrimidine

AU Fel'dman, I. Kh.

SO Tr. Leningr. Khim.-Farmatsevt. Inst. (1962), (16), 25-8

DT Journal


LA Unavailable

AB cf. CA 55, 21136c, 23544f. For chem. and biol. study, a series of derivs. of I (R = OH) (Ia) was obtained. Ia (14.5 g.) and 30 ml. POCl<sub>3</sub> were heated at 100.degree. 3 hrs., excess POCl<sub>3</sub> removed under vacuum, ice, added, and NH<sub>4</sub>OH added to ppt. I (R = Cl) (Ib), 89%, m. 180-2.degree. (C<sub>2</sub>H<sub>4</sub>Cl<sub>2</sub>); Ac deriv. formed. I (R = SH) (Ic) treated with Ac<sub>2</sub>O gave the Ac deriv. of Ic, C<sub>7</sub>H<sub>9</sub>N<sub>3</sub>O<sub>5</sub>, m. 133-4.degree. (50% alc.). Ia (5 g.), 10 ml. ethylene oxide, and 15 ml. water were heated in a sealed tube at 50.degree. 10 hrs. to give 1-(.beta.-hydroxyethyl)-2-amino-4-methyldihydro-6-pyrimidinone, yield 68%, m. 187-8.degree. (1:2 alc.-ether), 1.69 g. of which and 1 ml. SOCl<sub>2</sub> were heated to soln. and cooled to give 1-(.beta.-chloroethyl)-2-amino-4-methyldihydro-6-pyrimidinone-HCl, yield 62%, m. 215-16.degree. (alc.). To a soln. of Ia (0.625 g.) in 3 ml. 15% NaOH with cooling, 0.8 g. MeSO<sub>2</sub>Cl is added to give I (R = MeSO<sub>3</sub>), 70%, m. 138-9.degree. (alc.). A mixt. of 1.4 g. Ib and 10 ml. BuOH was heated to soln., 1.05 g. HN-(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub> added, and the mixt. stirred at 130-40.degree. 6 hrs. to give I.HCl [R = N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>] (Id), 80%, m. 165-6.degree. (Me-OH). Id (2.5 g.) and 15 ml. dichloroethane was treated with cooling with 3 ml. SOCl<sub>2</sub> dropwise, and the mixt. heated at 80.degree. 20 min. and kept several hrs. to give I.HCl [R = N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>], yield 93%, m. 214-15.degree. (MeOH). Ib (5.72 g.), 9 g. H<sub>2</sub>NCH<sub>2</sub>CO<sub>2</sub>H, 2 g. Et<sub>3</sub>N, and 25 ml. HCONMe<sub>2</sub> was stirred 80-5 hrs. at 90-100.degree. to give I.HCl (R = NHCH<sub>2</sub>CO<sub>2</sub>H), m. 171-3.degree. (alc.). Ib (2.86 g.), 2 ml. H<sub>2</sub>NCH<sub>2</sub>CO<sub>2</sub>Et, and 13 ml. HCONMe<sub>2</sub> was heated at 70-80.degree. 68-70 hrs. to give I.HCl (R = NHCH<sub>2</sub>CO<sub>2</sub>Et), m. 218-19.degree. (alc.).

IT 92385-16-5, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, hydrochloride 93263-85-5, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester, hydrochloride (prepn. of)

RN 92385-16-5 CAPLUS


CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, hydrochloride (7CI) (CA INDEX NAME)



●x HCl

RN 93263-85-5 CAPLUS

CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)



● x HCl

L16 ANSWER 34 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1964:9987 CAPLUS

DN 60:9987

OREF 60:1829e-g

TI Potential antimetabolites. VII. Substituted N-4-pyrimidyl amino acids and their derivatives

AU Shvachkin, Yu. P.; Berestenko, M. K.

CS State Univ., Moscow

SO Zh. Obshch. Khim. (1963), 33(9), 2842-8

DT Journal


LA Unavailable

AB cf. CA 58, 3425a; 60, 654e. The following were prepd. as potential antimetabolites in protein-nucleic metabolism. PhCH<sub>2</sub>CH(NH<sub>2</sub>)CO<sub>2</sub>H refluxed in aq. NaOH with 2-amino-4chloro-5-nitro-6-methylpyrimidine (I) 40 min. gave after treatment with AcOH 72.8% N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)phenylalanine, decompd. 219-20.degree., .LAMBDA. 260 and 368-72 m.mu.; also formed in 41.7% yield from the corresponding Me ester (II) refluxed 3 hrs. in 2N HCl. Di-Na glutamate similarly gave 82.7% N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)glutamic acid, decompd. 213-14.degree., .LAMBDA. 367-9 m.mu.. Similarly, arginine gave 53.6% .alpha.-N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)arginine, m. 203-5.degree., .LAMBDA. 362-4 and 364-5 m.mu.. Phenylalanine Me ester-HCl treated with MeONa-MeOH at 0.degree., then with I, finally at room temp. 40 min., gave 54.2% II, m. 173.degree., .LAMBDA. 260-1 and 358 m.mu., which also formed by esterifying the free amino acid with MeOH.HCl 3 hrs. at reflux and 12 hrs. at room temp. in 92.1% yield. Similarly tyrosine Me ester-HCl and I in MeONa-MeOH-Me<sub>2</sub>CO gave in 0.5 hr. at 0.degree. and 1 hr. at room temp. 54.6% N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)tyrosine Me ester, m. 173.degree., .LAMBDA. 259 and 361-3 m.mu.. Similarly were prepd.: N-(2-amino-5-nitro-6methyl-14-pyrimidyl) valine Me ester, 70.4%, m. 163.degree., 259 and 362-5 m.mu.; N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)leucine Me ester, 65, m. 153.degree., .LAMBDA. 261 and 360 m.mu.; N-(2-amino-5-nitro-6methyl-4-pyrimidyl)glutamic acid di-Me ester, 46.7, m. 112.degree., .LAMBDA. 257-9 and 360 m.mu.; N-(2-amino-5-nitro-6-methyl-4-pyrimidyl)phenylalanylglycine Me ester, 58, m. 170-1.degree. (MeOH), .LAMBDA. 262 and 362-3 m.mu.. The electrophoretic mobilities in 30% AcOH or in 0.1N borax are reported, as are the R<sub>f</sub> values on paper in isoPrOH-NH<sub>4</sub>OH-H<sub>2</sub>O, BuOH-H<sub>2</sub>O-AcOH, and BuOH satd. with H<sub>2</sub>O.

IT 91194-85-3, Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 92286-86-7, Arginine, N2-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- 93002-46-1, Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 93537-11-2, Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 94823-79-7, Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (prepn. of)


RN 91194-85-3 CAPLUS

CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)




RN 92286-86-7 CAPLUS

CN Arginine, N2-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 93002-46-1 CAPLUS

CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)




RN 93537-11-2 CAPLUS

CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 94823-79-7 CAPLUS

CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)



L16 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1963:462818 CAPLUS

DN 59:62818

OREF 59:11651c-d

TI Structure of proteins. VIII. Preparation of nitropyrimidylamino acids

AU Scoffone, Ernesto; Signor, Angelo; Biondi, Laura

CS Univ. Padua, Italy

SO Gazz. Chim. Ital (1963), 93(1-2), 81-9

DT Journal


LA Unavailable

AB 2-Chloro-5-nitro- (I), 2-methyl-4-chloro-5-nitro-6-amino-(II), and 2-amino-4-chloro-5-nitro-6-methylpyrimidine (III) were similarly treated with amino acids (amino acid and m.p. derivs. with I, II, III given): glycine, 188.degree., 290.degree., 240.degree.; DL-alanine, 187.degree., 253.degree., 230.degree.; DL-serine, 208.degree., 240.degree., 220.degree.; DL-valine, 151.degree., --, 220.degree.; L-leucine, 94.degree., 240.degree., --; DL-phenylalanine, 193.degree., 236.degree., 210.degree.; L-proline (IV), 178.degree., 260.degree., 135.degree.; L-tyrosine --, --, 164.degree.. All I derivs. had .lambda. useful for detn. at 340 .+- 2 m.mu. (except IV, 360 m.mu.), II derivs., at 345 m.mu. (IV, 340 m.mu.), and III derivs., at 361 m.mu. (IV 380 m.mu.) and 260 m.mu. (IV, 274 m.mu.). The stability of these derivs. was greater than of the pyridine derivs.; leucine and phenylalanine derivs. with II gave a 0% hydrolysis test. II is the preferred reagent.

IT 89854-39-7, Glycine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (prepn. of)

RN 89854-39-7 CAPLUS

CN Glycine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



L16 ANSWER 36 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1963:73327 CAPLUS

DN 58:73327

OREF 58:12559b-c

TI Synthesis of some N-pyrimidylamino acids. III

AU Roy-Burman, P.; Sen, D.

CS Univ. Colls. Sci. Technol., Calcutta

SO Naturwissenschaften (1962), 49, 494-5

DT Journal


LA English

AB cf. CA 57, 824b. The following were prepd.: I [R = CH(CH<sub>2</sub>OH)CO<sub>2</sub>H], m. 213-14.degree. (decompn.), .lambda. 270 m.mu.; I (R = C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H-p), chars without melting 338-40.degree., .lambda. 300 m.mu.; I (R = CH<sub>2</sub>CONHNH<sub>2</sub>), m. 205-9.degree., .lambda. 270 m.mu.; II (R = C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H-p), m. 312.degree. (decompn.) .lambda. 272 and 310 m.mu.; II (R = C<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H-p, m. >360.degree., .lambda. 265 and 305 m.mu.; and III (R = CH<sub>2</sub>CO<sub>2</sub>H), m. >360.degree., .lambda. 275 m.mu..

IT 89465-54-3, Glycine, N-(2,6-diamino-4-pyrimidinyl)- (prepn. of)

RN 89465-54-3 CAPLUS

CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)





L16 ANSWER 37 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1963:48342 CAPLUS

DN 58:48342

OREF 58:8252g-h, 8253a

TI N-(5-Arylazo-4-pyrimidyl)amino acids as growth inhibitors of *Streptococcus faecalis*

AU Roy-Burman, P.; Sen, D.

CS Univ. Calcutta

SO Nature (1962), 196, 1316

DT Journal

LA Unavailable


AB cf. Tanaka, et al., CA 54, 21111g. Seven new compds. were prepd. (CA 55, 10456f) and their inhibitory action tested on certain microorganisms. All the compds. inhibited the growth of *S. faecalis*, and all were competitive antagonists to pteroylglutamic acid (PGA) and leucovorin. Inhibition of *S. faecalis* was as follows: (concn. .gamma./ml. required for 50% inhibition of growth in the presence of PGA (0.001 .gamma./ml.)): I, 0.105; II (R = H), 1.07; II (R = Me) 2.25; II (R = Et), 2.7; II (R = iso-Pr), 7.19; II (R = sec-Bu), 7.8; II (R: benzyl), 22.8.

IT **94264-54-7**, Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]-

(Staphylococcus faecalis response)

RN 94264-54-7 CAPLUS


CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)



IT **93727-00-5**, Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- **94093-95-5**, Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- **94264-54-7**, Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylbutyl)amino]-6-methyl-5-pyrimidinyl]azo]- **96063-58-0**, Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (Staphylococcus faecalis response to)


RN 93727-00-5 CAPLUS

CN Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 94093-95-5 CAPLUS

CN Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 94264-54-7 CAPLUS

CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)



RN 96063-58-0 CAPLUS

CN Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (7CI) (CA INDEX NAME)



L16 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1963:20731 CAPLUS

DN 58:20731

OREF 58:3425a-c

TI Nucleophilic displacement reactions in the synthesis of N-4-pyrimidyl amino acids and their derivatives

AU Shvachkin, Yu. P.; Berestenko, M. K.

CS State Univ., Moscow

SO Zh. Obshch. Khim. (1962), 32, 1712-13

DT Journal


LA Unavailable

AB Reaction of 2-amino-4-chloro-5-nitro-6-methylpyrimidine with Na salts or esters of amino acids readily gave I (R given): HO<sub>2</sub>CCH(CH<sub>2</sub>Ph), decomp. at 219-20.degree.; HO<sub>2</sub>CCH(CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H), decomp. at 213-14.degree.; MeO<sub>2</sub>CCH(CH<sub>2</sub>Ph), m. 173.degree.; MeO<sub>2</sub>CCH(CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me), m. 112.degree.; MeO<sub>2</sub>CCH(CHMe<sub>2</sub>), m. 163.degree.; MeO<sub>2</sub>CCH(CH<sub>2</sub>CHMe<sub>2</sub>), m. 153.degree.; MeO<sub>2</sub>CCH(CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OH-p), m. 173.degree.; MeO<sub>2</sub>CCH<sub>2</sub>NHCOCH(CH<sub>2</sub>Ph), m. 170.degree.. The yields were 46-83%. Ultraviolet max. were given.

IT 91194-85-3, Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 92295-36-8, Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- 92556-22-4, Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester 93002-46-1, Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 93537-11-2, Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester 94823-79-7, Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (prepn. of)


RN 91194-85-3 CAPLUS

CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)  
(CA INDEX NAME)




RN 92295-36-8 CAPLUS

CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)




RN 92556-22-4 CAPLUS

CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester (7CI) (CA INDEX NAME)




RN 93002-46-1 CAPLUS

CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)




RN 93537-11-2 CAPLUS

CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)



RN 94823-79-7 CAPLUS

CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)



L16 ANSWER 39 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1962:404013 CAPLUS

DN 57:4013

OREF 57:824b-e

TI Synthesis of some N-pyrimidyl amino acids. II

AU Roy-Burman, P.; Len, D.; Guha, B. C.

CS Univ. Colls. Sci. and Technol., Calcutta

SO Naturwissenschaften (1961), 48, 737

DT Journal

LA English


AB cf. CA 55, 10456f. Various substituted carboxyalkylaminopyrimidines (I) were prepd. to give compds. with possible effect on tumor growth and on the growth of various microorganisms. The following I were obtained [R, R', m.p. (decompn.),  $\lambda$  (detd. in 0.1N HCl), and type (L or DL) given]: H, CH(CO<sub>2</sub>H)CH<sub>2</sub>CHMe<sub>2</sub> (I), 278.degree., 270, L; H, CH(CO<sub>2</sub>H)CHMeEt (II), 276-8.degree., 270, DL; H, CH(CO<sub>2</sub>H)Et (III), 284-6.degree., 270, DL; CH<sub>2</sub>(CO<sub>2</sub>H), H (IV), 289-92.degree. (vacuum sealed capillary), 270, -; CH(CO<sub>2</sub>H)Me, H (V), 222-5.degree., 209, DL; CH(CO<sub>2</sub>H)CH<sub>2</sub>Ph, H (VI), 260-3.degree., 270, DL; H, CH(CO<sub>2</sub>Et)CH<sub>2</sub>CHMe<sub>2</sub> (VII), 119-20.degree. (no decompn.), -, -; CH<sub>2</sub>(CO<sub>2</sub>Et), H (VIII), 136-7.5.degree. (no decompn.), -, -. I-VI (white, amphoteric compds.) were prepd. by condensation of 2-amino-4-chloro-6-methylpyrimidine or of 2-chloro-4-amino-6-methylpyrimidine with equimolar amts. of amino acids in an aq. medium in the presence of small amts. of HCl, VII and VIII by passing dry HCl through an EtOH suspension (heated to 80.degree.) of I and II, resp., followed by treatment with aq. Na<sub>2</sub>CO<sub>3</sub>. III, IV, and V were purified by crystn. from H<sub>2</sub>O, I, II, VI by dissolving in ammonia and pptg. by addn. of HCl to pH 6-7.degree., VII and VIII by dissolving in EtOH and pptg. with H<sub>2</sub>O.

IT 92107-70-5, Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester

(prepn. of)

RN 92107-70-5 CAPLUS

CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (7CI) (CA INDEX NAME)



L16 ANSWER 40 OF 40 CAPLUS COPYRIGHT 2003 ACS

AN 1961:54318 CAPLUS

DN 55:54318

OREF 55:10456f-g

TI N-Pyrimidyl amino acids

AU Roy-Burman, P.; Roy, Dolly; Sen, D.

CS Univ. Colls. Sci. Technol., Calcutta

SO Naturwissenschaften (1960), 47, 515-16

DT Journal

LA English

AB 2-Amino-4-chloro-6-methylpyrimidine was condensed with equimolar amts. of amino acids in an aq. medium in the presence of small amts. of HCl. The 2-amino-4-chloro-6-methylpyrimidyl derivs. of the following were prepd. and recrystd. from H<sub>2</sub>O [m.p. (decompn.) given]: glycine, 298.degree.; DL-alanine, 290.degree.; DL-phenylalanine, 275.degree.; DL-valine, 287.degree.; DL-serine, 264.degree.. The ultraviolet absorption of these compds. showed a peak near 270 m.mu. (in 0.1N HCl).


IT 89897-36-9, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-

90198-25-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-

92296-32-7, Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl-  
(prepn. of)


RN 89897-36-9 CAPLUS

CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-25-7 CAPLUS

CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 92296-32-7 CAPLUS

CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA INDEX NAME)





=> d his

(FILE 'HOME' ENTERED AT 18:19:19 ON 21 FEB 2003)

FILE 'REGISTRY' ENTERED AT 18:19:25 ON 21 FEB 2003

L1 STRUCTURE UPLOADED  
L2 21 S L1 SSS SAM  
L3 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045  
L4 STRUCTURE UPLOADED  
L5 QUE L4 NOT L3  
L6 50 S L5 SSS SAM  
L7 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045  
L8 STRUCTURE UPLOADED  
L9 QUE L8 NOT L7  
L10 50 S L9 SSS SAM  
L11 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045  
L12 STRUCTURE UPLOADED  
L13 QUE L12 NOT L11  
L14 3 S L13 SSS SAM  
L15 88 S L13 SSS FUL

FILE 'CAPLUS' ENTERED AT 18:31:01 ON 21 FEB 2003

L16 40 S L15

FILE 'CAOLD' ENTERED AT 18:31:52 ON 21 FEB 2003

=> s l15

L17 12 L15

=> d l17 1-12 bib,hitstr

L17 ANSWER 1 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA62:5278h CAOLD


TI pteridine derivs. - (IX) 2,6-diamino-4-hydroxypteridine and related dihydropteridines

AU Stuart, Alexander; West, D. W.; Wood, H. C. S.

IT 1140-88-1 1154-85-4 14699-57-1


RN 1140-88-1 CAOLD

CN Acetamide, 2-[(2-amino-6-hydroxy-5-nitro-4-pyrimidinyl)amino]- (7CI, 8CI)  
(CA INDEX NAME)




RN 1154-85-4 CAOLD

CN Alanine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 14699-57-1 CAOLD

CN Glycine, N-(2-amino-1,6-dihydro-5-nitro-6-oxo-4-pyrimidinyl)-, ethyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 2 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA61:15067a CAOLD


TI effect of a number of N-pyrimidyl amino acids and of some of their 5-arylaazo derivs. on the growth of certain microorganisms

AU Roy-Burman, P.; Sen, D.

IT 89465-54-3 89897-36-9 90198-25-7  
 90198-46-2 90649-20-0 91253-20-2  
 91253-21-3 91717-29-2 92296-32-7  
 93432-76-9 93727-00-5 94093-95-5  
 94264-54-7 95126-82-2 96063-58-0


RN 89465-54-3 CAOLD

CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 89897-36-9 CAOLD

CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-25-7 CAOLD

CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-46-2 CAOLD

CN Serine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90649-20-0 CAOLD

CN Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)




RN 91253-20-2 CAOLD

CN Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 91253-21-3 CAOLD

CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 91717-29-2 CAOLD

CN Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 92296-32-7 CAOLD

CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA INDEX NAME)




RN 93432-76-9 CAOLD

CN Benzoic acid, p-[[2-amino-4-[(carboxymethyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 93727-00-5 CAOLD

CN Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 94093-95-5 CAOLD

CN Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 94264-54-7 CAOLD

CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]-  
(7CI) (CA INDEX NAME)




RN 95126-82-2 CAOLD

CN Benzoic acid, p-[[2-amino-4-[(1-carboxyethyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 96063-58-0 CAOLD

CN Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (7CI) (CA INDEX NAME)



L17 ANSWER 3 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA60:10681b CAOLD


TI synthesis of some simple 2-substituted pyrimidines and 2,2'-bipyrimidines, and their anal. applications

AU Bly, Donald D.; Mellon, M. G.

IT 92385-16-5 93263-85-5

RN 92385-16-5 CAOLD


CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, hydrochloride (7CI) (CA INDEX NAME)



●x HCl

RN 93263-85-5 CAOLD

CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester, hydrochloride (7CI) (CA INDEX NAME)



●x HCl

L17 ANSWER 4 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA60:1829g CAOLD


TI potential antimetabolites - (VIII) acyclic amino acids from pyrimidines

AU Shvachkin, Yu. P.; Syrtsova, L. A.


IT 91194-85-3 91647-59-5 93002-46-1

94823-79-7


RN 91194-85-3 CAOLD

CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)  
(CA INDEX NAME)

RN 91647-59-5 CAOLD

CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, dimethyl ester  
(7CI) (CA INDEX NAME)


RN 93002-46-1 CAOLD

CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)  
(CA INDEX NAME)

RN 94823-79-7 CAOLD



CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-, methyl ester (7CI) (CA INDEX NAME)



L17 ANSWER 5 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA60:1829e CAOLD

TI potential antimetabolites - (VII) substituted N-(4-pyrimidyl)amino acids and their derivs.


AU Shvachkin, Yu. P.; Berestenko, M. K.

IT 91086-76-9 92286-86-7 92295-36-8

92556-22-4 93537-11-2


RN 91086-76-9 CAOLD

CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 92286-86-7 CAOLD

CN Arginine, N2-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 92295-36-8 CAOLD

CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)




RN 92556-22-4 CAOLD

CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester (7CI) (CA INDEX NAME)



RN 93537-11-2 CAOLD

CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)  
(CA INDEX NAME)



L17 ANSWER 6 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA59:11651c CAOLD


TI structure of proteins - (VIII) prepn. of nitropyrimidylamino acids

AU Scoffone, Ernesto.; Signor, A.; Biondi, L.

IT 89854-39-7 90085-29-3 91978-49-3  
92295-36-8 92295-39-1 92347-91-6


RN 89854-39-7 CAOLD

CN Glycine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 90085-29-3 CAOLD

CN Serine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 91978-49-3 CAOLD

CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 92295-36-8 CAOLD

CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)




RN 92295-39-1 CAOLD

CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 92347-91-6 CAOLD

CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



L17 ANSWER 7 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA58:12559b CAOLD


TI synthesis of some N-pyrimidyl amino acids - (III)

AU Roy-Burman, P.; Sen, D.

IT **89465-54-3**

RN 89465-54-3 CAOLD

CN Glycine, N-(2,6-diamino-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



L17 ANSWER 8 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA58:8252h CAOLD

TI N-(5-arylazo-4-pyrimidyl)amino acids as growth inhibitors of *Streptococcus faecalis*


AU Roy-Burman, P.; Sen, D.

IT 93432-76-9 93727-00-5 94093-95-5

94264-54-7 95126-82-2 96063-58-0


RN 93432-76-9 CAOLD

CN Benzoic acid, p-[[2-amino-4-[(carboxymethyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 93727-00-5 CAOLD

CN Benzoic acid, p-[[2-amino-4-[(1-carboxy-2-methylpropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 94093-95-5 CAOLD

CN Benzoic acid, p-[[2-amino-4-[(1-carboxypropyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)




RN 94264-54-7 CAOLD

CN Isoleucine, N-[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]- (7CI) (CA INDEX NAME)




RN 95126-82-2 CAOLD

CN Benzoic acid, p-[[2-amino-4-[(1-carboxyethyl)amino]-6-methyl-5-pyrimidinyl]azo]- (7CI) (CA INDEX NAME)



RN 96063-58-0 CAOLD

CN Hydrocinnamic acid, .alpha.-[[2-amino-5-[(p-carboxyphenyl)azo]-6-methyl-4-pyrimidinyl]amino]- (7CI) (CA INDEX NAME)





L17 ANSWER 9 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA58:3425a CAOLD

TI nucleophilic displacement reactions in the synthesis of  
N-(4-pyrimidyl)amino acids and their derivs.

AU Shvachkin, Yu. P.; Berestenko, M. K.


TI sulfanilamidopyrimidines - (II) 4-sulfanilamidopyrimidines and certain  
4,6-disubstituted pyrimidines

AU Taft, William E.; Shepherd, R. G.

IT 91086-76-9 91194-85-3 91647-59-5  
92295-36-8 92556-22-4 93002-46-1  
93537-11-2 94823-79-7


RN 91086-76-9 CAOLD

CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)- (7CI) (CA  
INDEX NAME)




RN 91194-85-3 CAOLD

CN Valine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)  
(CA INDEX NAME)




RN 91647-59-5 CAOLD

CN Glutamic acid, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, dimethyl ester  
(7CI) (CA INDEX NAME)




RN 92295-36-8 CAOLD

CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)




RN 92556-22-4 CAOLD

CN Alanine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenyl-, methyl ester (7CI) (CA INDEX NAME)




RN 93002-46-1 CAOLD

CN Leucine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI) (CA INDEX NAME)




RN 93537-11-2 CAOLD

CN Tyrosine, N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-, methyl ester (7CI)  
(CA INDEX NAME)



RN 94823-79-7 CAOLD

CN Glycine, N-[N-(2-amino-6-methyl-5-nitro-4-pyrimidinyl)-3-phenylalanyl]-,  
methyl ester (7CI) (CA INDEX NAME)



L17 ANSWER 10 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA57:824b CAOLD

TI synthesis of some N-pyrimidyl amino acids - (II)


AU Roy-Burman, P.; Sen, D.; Guha, B. C.

IT 90649-20-0 91253-20-2 91253-21-3

92107-70-5


RN 90649-20-0 CAOLD

CN Butyric acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (7CI) (CA INDEX NAME)




RN 91253-20-2 CAOLD

CN Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)




RN 91253-21-3 CAOLD

CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (7CI) (CA INDEX NAME)



RN 92107-70-5 CAOLD

CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)-, ethyl ester (7CI) (CA INDEX NAME)



L17 ANSWER 11 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA55:10456g CAOLD

TI structure of muta-aspergillic acid


AU Nakamura, Seiji

IT 89897-36-9 90198-25-7 90198-46-2

91717-29-2 92296-32-7


RN 89897-36-9 CAOLD

CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-25-7 CAOLD

CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)




RN 90198-46-2 CAOLD

CN Serine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 91717-29-2 CAOLD


CN Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- (6CI, 7CI) (CA INDEX NAME)



RN 92296-32-7 CAOLD

CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA

INDEX NAME)



L17 ANSWER 12 OF 12 CAOLD COPYRIGHT 2003 ACS

AN CA54:7712i CAOLD


TI hydropteridines - (V) 7,8-dihydro-6-hydroxy-4-pteridinecarboxylic acids

AU Clark, Jim; Layton, A. J.

IT 99988-33-7 100140-57-6


RN 99988-33-7 CAOLD

CN 4-Pyrimidinecarboxylic acid, 2-amino-6-[(carboxymethyl)amino]-5-nitro-, diethyl ester (6CI) (CA INDEX NAME)



RN 100140-57-6 CAOLD

CN 4-Pyrimidinecarboxylic acid, 2,5-diamino-6-[(carboxymethyl)amino]-, diethyl ester (6CI) (CA INDEX NAME)





09/907,273 (subgenus around elected species)

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

31.84

369.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-26.04

STN INTERNATIONAL LOGOFF AT 18:32:33 ON 21 FEB 2003